FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059165344> ?p ?o ?g. }

• W2059165344 endingPage "999" @default.
• W2059165344 startingPage "990" @default.
• W2059165344 abstract "Pegylated interferon and ribavirin (PEG-IFN/RBV) therapy for recurrent hepatitis C after liver transplantation (LT) is associated with a lower sustained virological response (SVR) rate as well as more frequent side effects compared to non-transplant patients. We aimed to determine the incidence and clinical characteristics of LT recipients with recurrent hepatitis C who developed immunological dysfunction (ID) during or after PEG-IFN/RBV therapy and to assess its impact on patient and graft survival. Seventy-four deceased donor LT recipients with histological recurrence of hepatitis C were treated with PEG-IFN/RBV from 1/00 to 12/08. ID was defined as biopsy-proven rejection or moderate plasma cell hepatitis. Patients were followed up until death, re-LT or 30 September 2011. Twelve patients (16 %) had ID, 8 (10.7 %) had cholestasis without ID, while 54 had no ID/cholestasis during or after discontinuation of PEG-IFN/RBV therapy. Biopsy-proven acute cellular rejection prior to (hazard ratio = 4.87, p = 0.009) and type of immunosuppression at the time of initiation of PEG-IFN/RBV were the only independent predictors of ID. Patients who were on tacrolimus at the time of initiation of PEG-IFN/RBV had a significantly lower risk of ID compared to those who were on cyclosporine (HR 0.254, p = 0.023). Patients with ID had a trend toward a lower SVR rate (25 vs. 54 %, p = 0.18) and a significantly higher rate of graft failure (33 vs. 4 %, p = 0.004) compared to patients with no ID/cholestasis. ID is common during or after PEG-IFN/RBV therapy for recurrent hepatitis C and frequently associated with decreased graft survival, trending toward low rates of SVR. Careful monitoring of liver biochemistries during or after PEG-IFN/RBV therapy with a low threshold to biopsy patients and particularly those receiving cyclosporine-based immunosuppression may improve outcomes in these patients." @default.
• W2059165344 created "2016-06-24" @default.
• W2059165344 creator A5011485200 @default.
• W2059165344 creator A5025478304 @default.
• W2059165344 creator A5042803304 @default.
• W2059165344 creator A5046039724 @default.
• W2059165344 creator A5053592727 @default.
• W2059165344 creator A5054920863 @default.
• W2059165344 creator A5063597784 @default.
• W2059165344 creator A5077140895 @default.
• W2059165344 date "2013-04-25" @default.
• W2059165344 modified "2023-10-18" @default.
• W2059165344 title "Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival" @default.
• W2059165344 cites W1963893690 @default.
• W2059165344 cites W1974266777 @default.
• W2059165344 cites W1976743239 @default.
• W2059165344 cites W1979815055 @default.
• W2059165344 cites W1983627321 @default.
• W2059165344 cites W1993628301 @default.
• W2059165344 cites W1993823188 @default.
• W2059165344 cites W2015770655 @default.
• W2059165344 cites W2018587017 @default.
• W2059165344 cites W2034945905 @default.
• W2059165344 cites W2036535010 @default.
• W2059165344 cites W2043067438 @default.
• W2059165344 cites W2059114505 @default.
• W2059165344 cites W2061339235 @default.
• W2059165344 cites W2064677954 @default.
• W2059165344 cites W2070731552 @default.
• W2059165344 cites W2076158870 @default.
• W2059165344 cites W2084330765 @default.
• W2059165344 cites W2096116739 @default.
• W2059165344 cites W2099692746 @default.
• W2059165344 cites W2108840780 @default.
• W2059165344 cites W2112888014 @default.
• W2059165344 cites W2124184742 @default.
• W2059165344 cites W2125242992 @default.
• W2059165344 cites W2127746188 @default.
• W2059165344 cites W2128685489 @default.
• W2059165344 cites W2146454939 @default.
• W2059165344 cites W2154485684 @default.
• W2059165344 cites W2167632306 @default.
• W2059165344 cites W2171188327 @default.
• W2059165344 cites W2171564245 @default.
• W2059165344 cites W2318197279 @default.
• W2059165344 cites W4255388685 @default.
• W2059165344 doi "https://doi.org/10.1007/s12072-013-9436-1" @default.
• W2059165344 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4371864" @default.
• W2059165344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25815091" @default.
• W2059165344 hasPublicationYear "2013" @default.
• W2059165344 type Work @default.
• W2059165344 sameAs 2059165344 @default.
• W2059165344 citedByCount "13" @default.
• W2059165344 countsByYear W20591653442013 @default.
• W2059165344 countsByYear W20591653442014 @default.
• W2059165344 countsByYear W20591653442015 @default.
• W2059165344 countsByYear W20591653442016 @default.
• W2059165344 countsByYear W20591653442017 @default.
• W2059165344 countsByYear W20591653442018 @default.
• W2059165344 countsByYear W20591653442019 @default.
• W2059165344 crossrefType "journal-article" @default.
• W2059165344 hasAuthorship W2059165344A5011485200 @default.
• W2059165344 hasAuthorship W2059165344A5025478304 @default.
• W2059165344 hasAuthorship W2059165344A5042803304 @default.
• W2059165344 hasAuthorship W2059165344A5046039724 @default.
• W2059165344 hasAuthorship W2059165344A5053592727 @default.
• W2059165344 hasAuthorship W2059165344A5054920863 @default.
• W2059165344 hasAuthorship W2059165344A5063597784 @default.
• W2059165344 hasAuthorship W2059165344A5077140895 @default.
• W2059165344 hasBestOaLocation W20591653442 @default.
• W2059165344 hasConcept C126322002 @default.
• W2059165344 hasConcept C203014093 @default.
• W2059165344 hasConcept C207103383 @default.
• W2059165344 hasConcept C2522874641 @default.
• W2059165344 hasConcept C2775934546 @default.
• W2059165344 hasConcept C2776408679 @default.
• W2059165344 hasConcept C2776455275 @default.
• W2059165344 hasConcept C2776461080 @default.
• W2059165344 hasConcept C2777766500 @default.
• W2059165344 hasConcept C2778593092 @default.
• W2059165344 hasConcept C2779609443 @default.
• W2059165344 hasConcept C2780040827 @default.
• W2059165344 hasConcept C2780252810 @default.
• W2059165344 hasConcept C2911091166 @default.
• W2059165344 hasConcept C41260117 @default.
• W2059165344 hasConcept C44249647 @default.
• W2059165344 hasConcept C71924100 @default.
• W2059165344 hasConcept C90924648 @default.
• W2059165344 hasConceptScore W2059165344C126322002 @default.
• W2059165344 hasConceptScore W2059165344C203014093 @default.
• W2059165344 hasConceptScore W2059165344C207103383 @default.
• W2059165344 hasConceptScore W2059165344C2522874641 @default.
• W2059165344 hasConceptScore W2059165344C2775934546 @default.
• W2059165344 hasConceptScore W2059165344C2776408679 @default.
• W2059165344 hasConceptScore W2059165344C2776455275 @default.
• W2059165344 hasConceptScore W2059165344C2776461080 @default.
• W2059165344 hasConceptScore W2059165344C2777766500 @default.
• W2059165344 hasConceptScore W2059165344C2778593092 @default.

• next